A phase II trial to investigate dodecafluoropentane emulsion (DDFPe) in patients with stroke
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Perflenapent (Primary)
- Indications Stroke
- Focus Therapeutic Use
- 02 Feb 2018 New trial record
- 31 Jan 2018 According to a NuvOx Pharmaceuticals media release, the FDA has allowed the company to proceed with this trial. The trial will be run in cooperation with the Banner University Medical Center in Tucson, Arizona.